Ever wondered how a single month could shake up the world of diabetes and weight management? November 2025 delivered some game-changing news in endocrinology that you might have overlooked. Dive in as we unpack the key developments, from groundbreaking drug trials to expert discussions, all aimed at helping both patients and clinicians navigate these evolving treatments. And this is the part most people miss: how these updates aren't just about science—they're sparking debates on accessibility, ethics, and the future of personalized medicine.
While endocrinology took a relatively subdued pace in November 2025, it wasn't entirely uneventful. No major nods from the US Food and Drug Administration (FDA) graced the headlines, but the glucagon-like peptide-1 receptor agonists—those medications that mimic a hormone to help regulate blood sugar and appetite—kept making waves by expanding into new medical fields like kidney care and heart health. Novo Nordisk, a big player in this space, experienced a wild ride: their drug semaglutide didn't live up to hopes in slowing Alzheimer's disease progression, yet their experimental treatment amycretin shone brightly in weight loss studies for people with type 2 diabetes (T2D), outperforming a placebo in exciting ways.
But here's where it gets controversial: should we celebrate these advancements in diabetes meds, or worry about their soaring costs and potential overuse? Our team at HCPLive has rounded up the top 5 impactful stories from endocrinology last month. Let's explore them together, with some beginner-friendly explanations to make these complex topics clearer.
Trial Results
Novo Nordisk's Amycretin Outshines Placebo in Promoting Weight Loss
On November 25, 2025, Novo Nordisk shared triumphant results from their phase 2 trial of amycretin, a novel medication that can be taken either once a week via injection or daily by mouth. This drug helped patients with type 2 diabetes shed pounds effectively and lower their HbA1c levels—a key measure of average blood sugar over time, which is crucial for managing diabetes and preventing complications like nerve damage or heart issues. Building on this success, the company plans to launch phase 3 trials sometime in 2026, potentially bringing this treatment closer to everyday use.
Exploratory Amylin Agonist Eloralintide Edges Out Placebo in Obesity Control
Eloralintide, a once-weekly injectable that targets amylin receptors, outperformed placebo in reducing body weight among adults dealing with obesity and at least one related health issue, such as high blood pressure or sleep apnea. By possibly boosting feelings of fullness, it helps cut down on calorie consumption—think of it as a tool that tricks your brain into feeling satisfied sooner, making it easier to stick to a healthier diet. Doctors are now studying it further, both on its own and paired with tirzepatide (another GLP-1 drug), for managing weight in people who are overweight or obese, including those with type 2 diabetes.
Semaglutide Offers Heart and Kidney Protections in Chronic Kidney Disease, With or Without Diabetes
A fresh meta-analysis combining data from five randomized trials revealed that semaglutide provides solid safety benefits for individuals with chronic kidney disease (CKD), a condition where the kidneys don't function properly, regardless of whether they have diabetes. This drug slashed risks of serious heart events, kidney problems, and heart-related deaths. Researchers emphasize the need to broaden our understanding of GLP-1 medications in kidney health, suggesting they could become a staple in preventing cardiovascular complications—imagine a treatment that not only controls blood sugar but also shields vital organs from damage.
Other Updates
Diabetes Dialogue: Insights on Dexcom G7 Launch and Semaglutide Cost Shifts
In a recent Diabetes Dialogue podcast episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, broke down Dexcom's rollout of the new 15-day G7 continuous glucose monitor sensor. Set to hit durable medical equipment providers on December 1 and pharmacies in January 2026, this sensor seamlessly connects to existing apps and keeps its high accuracy—plus, it lasts up to 15.5 days thanks to a 12-hour buffer if needed. They also addressed big price drops for Ozempic and Wegovy (both semaglutide-based drugs), now starting at just $199 for the first two months, then $349 ongoing. For beginners, these sensors are like wearable tech that tracks blood sugar in real-time, empowering patients to make informed decisions about insulin and diet, while the pricing changes aim to make these lifesaving meds more accessible.
Diabetes Dialogue: Semaglutide Stumbles in Alzheimer's, While Tirzepatide Triumphs in Type 1 Diabetes
Isaacs and Bellini tackled Novo Nordisk's setbacks in the Evoke and Evoke+ phase 3 trials, where oral semaglutide at 14 mg daily failed to halt the advancement of Alzheimer's disease, despite some biomarker improvements like reduced inflammation. The company decided to halt a planned year-long extension, highlighting the challenges in repurposing diabetes drugs for brain disorders. On a brighter note, the TIRTLE phase 2 trial demonstrated tirzepatide's effectiveness in helping adults with type 1 diabetes (T1D)—a condition where the body attacks its own insulin-producing cells—lose weight, better control blood sugar (lowering HbA1c), and even cut down on daily insulin needs without major side effects. This dual win shows promise for treating T1D more holistically, but it raises questions: are we overlooking the broader impacts of these drugs on non-diabetes conditions?
Newsletter
Stay ahead of the curve with thousands of healthcare pros by subscribing to HCPLive—get the latest on cutting-edge therapies, trial insights, and expert advice delivered straight to your inbox.
What do you think? Are these breakthroughs in endocrinology a step toward revolutionizing patient care, or do they risk widening inequalities in access to expensive treatments? Do you agree that repurposing diabetes drugs for other diseases like Alzheimer's is worth the gamble, or is it a distraction from core diabetes research? Share your thoughts in the comments—let's debate and learn together!
